Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported R&D Expense of $5.57 million for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.57M | +15.6% |
| 2024 | $4.82M | -17.4% |
| 2023 | $5.83M | -12.8% |
| 2022 | $6.69M | +17.7% |
| 2021 | $5.68M | -1.5% |
| 2020 | $5.77M | -15.9% |
| 2019 | $6.87M | -9.3% |
| 2018 | $7.58M | +77.0% |
| 2017 | $4.28M | +34.2% |
| 2016 | $3.19M | -17.1% |
| 2015 | $3.85M | +13.5% |
| 2014 | $3.39M | -39.6% |
| 2013 | $5.62M | +10.2% |
| 2012 | $5.10M | +1.3% |
| 2011 | $5.03M | +16.2% |
| 2010 | $4.33M | -13.3% |
| 2009 | $4.99M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.25M | -4.0% | -14.6% |
| June 30, 2025 | $1.47M | +38.6% | +13.4% |
| March 31, 2025 | $1.30M | +11.8% | -0.8% |
| September 30, 2024 | $1.31M | -32.1% | +23.3% |
| June 30, 2024 | $1.06M | -7.5% | -8.6% |
| March 31, 2024 | $1.16M | -22.8% | -39.8% |
| September 30, 2023 | $1.92M | +12.3% | +68.1% |
| June 30, 2023 | $1.15M | -37.2% | -23.6% |
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +15.6% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, CUMBERLAND PHARMACEUTICALS INC’s r&d expense has grown by 11.5% (from $4.99 million to $5.57 million).
- The most recent figure is from CUMBERLAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: